Taiho Oncology Set to Showcase Zipalertinib Data at ESMO 2025 in Berlin Taiho Oncology will present key findings from the REZILIENT2 trial of zipalertinib at ESMO Congress 2025, focusing on NSCLC patients with unique mutations.

Taiho Oncology Set to Showcase Zipalertinib Data at ESMO 2025 in Berlin #None #Berlin #Taiho_Oncology #Zipalertinib #REZILIENT2